EXOZYMES INC.

Exozymes Inc.

Biotechnology Healthcare Monrovia, CA, United States EXOZ (NCM)

eXoZymes, Inc. operates as a development stage biotechnology company. The company focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Other Biotechnology Companies

View All →

Frequently Asked Questions

Has EXOZYMES INC. had layoffs?
No layoff events have been recorded for EXOZYMES INC. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does EXOZYMES INC. have?
EXOZYMES INC. has approximately 31 employees.
What industry is EXOZYMES INC. in?
EXOZYMES INC. operates in the Biotechnology industry, within the Healthcare sector.
Is EXOZYMES INC. a publicly traded company?
Yes, EXOZYMES INC. is publicly traded under the ticker symbol EXOZ on the NCM. The company has a market capitalization of approximately $0.10 billion.
Where is EXOZYMES INC. headquartered?
EXOZYMES INC. is headquartered in Monrovia, CA, United States at 750 Royal Oaks Drive, Monrovia, CA 91016, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.